• Fulcrum Therapeutics to Host First Quarter 2022 Financial Results Conference Call and Webcast on Monday, May 9, 2022 at 8:00 a.m. ET

    Source: Nasdaq GlobeNewswire / 02 May 2022 08:00:02   America/New_York

    CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2022 financial results will be released on Monday, May 9, 2022 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

    Dial-in Number
    U.S./Canada Dial-in Number: 800-527-6973
    International Dial-in Number: 470-495-9162
    Conference ID: 1129907

    Replay Dial-in Number: 855-859-2056
    Replay International Dial-in Number: 404-537-3406
    Conference ID: 1129907

    An audio webcast will be accessible through the Investor Relations section of the company’s website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.

    About Fulcrum Therapeutics 
    Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. Fulcrum’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter @FulcrumTx and LinkedIn.

    Contacts:

    Naomi Aoki
    Senior Vice President, Corporate Communications and
    Investor Relations
    naoki@fulcrumtx.com

    Stephanie Ascher
    Stern Investor Relations, Inc.
    stephanie.ascher@sternir.com
    212-362-1200


    Primary Logo

Share on,